Best practice in cannabinoid-based R&D

Webinar: How to lower the risk of failure and increase the odds for scientific success

Cannabinoids, such as cannabidiol, hold great therapeutic promise. However, currently available drug delivery formats, as well as ongoing R&D, face challenges with regard to API absorption and patient compliance. In this webinar we share learnings from an in-depth technology assessment for improving the bioavailability of CBD while enabling patient-friendly formats with high API loading.

Speakers:

  • Zdravka Misic - Innovation Project Manager, dsm-firmenich
  • Christiane Schweiggert - Senior Scientist in Formulation & Materials Science, dsm-firmenich
Related content
Related articles
  • Elevating patient care with smart science and superior services

    Elevating patient care with smart science and superior services

    Explore how dsm-firmenich can help pharma raise the bar in patient-centricity and sustainability.

  • New CBD bioavailability study with CBtru®

    New CBD bioavailability study with CBtru®

    New study confirms CBtru®, a novel CBD drug product intermediate, demonstrates equal bioavailability to leading oil-based CBD drug product.

  • Synthetic vs natural CBD ingredients: The differences and why they matter

    Synthetic vs natural CBD ingredients: The differences and why they matter

    Explore five differences between synthetic and natural CBD APIs to inform your next research and development project.

How can we help you?

  • New partnership request

    Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.

  • Sample request

    Don’t just take our word for it. Discover how our solutions can support your product development journey. 

  • Quote request

    Tell us about your project needs. We’ll build you a tailored quote.